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Background: The crosstalk between Hedgehog (HH) signaling and other signal transduction cascades has been
extensively studied in different cancers. In neuroblastoma, mTOR/S6K1 signaling is known to have a role in the
development of this disease and recent evidence also implicates the HH pathway. Moreover, S6K1 kinase has been
shown to phosphorylate GLI1, the effector of HH signaling, promoting GLI1 transcriptional activity and oncogenic
function in esophageal adenocarcinoma. In this study, we examined the possible interplay of S6K1 and GLI1
signaling in neuroblastoma.
Methods: siRNA knockdowns were used to suppress S6K1 and GLI1 expression, and the siRNA effects were
validated by real-time PCR and Western blotting. Cell proliferation analysis was performed with the EdU incorporation
assay. Cytotoxic analysis with increasing concentrations of PI3K/mTOR and GLI inhibitors, individually and in
combination, was used to determine drug response.
Results: Although knockdown of either S6K1 or GLI1 reduces the cellular proliferation of neuroblastoma cells,
there is little effect of S6K1 on the expression of GLI1 mRNA and protein and on the capacity of GLI1 to activate
target genes. No detectable phosphorylation of GLI1 is observed prior or following S6K1 knockdown. GLI1
overexpression can not rescue the reduced proliferation elicited by S6K1 knockdown. Moreover, inhibitors of
PI3K/mTOR and GLI signaling reduced neuroblastoma cell growth, but no additional growth inhibitory effects
were detected when the two classes of drugs were combined.
Conclusion: Our results demonstrate that the impact of S6K1 kinase on neuroblastoma cells is not mediated
through modulation of GLI1 expression/activity.
Keywords: Hedgehog signaling, Protein phosphorylation, Signaling pathway crosstalk, Cellular proliferation,
Cell growth, Oncogenic signaling, mTOR/S6K1 signaling, Signaling inhibitorsBackground
Neuroblastoma is the most common and deadly tumor
of infancy [1,2]. It accounts for about 10% of childhood
cancers and the mortality reaches 12% [1,3,4]. Despite a
better understanding of the molecular, cellular and genetic
events that can lead to neuroblastoma development there is
still a need to explore new druggable targets for this disease.
The Hedgehog (HH) signaling pathway has critical
roles in embryonic development and tumorigenesis [5-8].
Aberrant activation of HH signaling is involved in several* Correspondence: peter.zaphiropoulos@ki.se
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unless otherwise stated.types of malignant tumors, including medulloblastoma,
rhabdomyosarcoma, basal cell carcinoma, and cancers of
the pancreas, colon, stomach, lung and prostate [9-11]. The
pathway is initiated by HH ligand [Sonic HH (SHH), Indian
HH (IHH), Desert HH (DHH)] [12,13] binding to Patched
(PTCH1, PTCH2), a twelve trans-membrane domain re-
ceptor protein. In the absence of ligands, PTCH inhibits
the signaling of the seven trans-membrane domain pro-
tein, the proto-oncogene Smoothened (SMO). Upon HH
binding, the inhibition of PTCH on SMO is relieved and
the signal is transduced to the terminal effectors, the GLI
(GLI1, GLI2, GLI3) transcription factors [12-16]. GLI1
not only acts as a signaling effector but also represents a
pathway target gene [16], amplifying the HH signal. Itsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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activity.
Recent studies indicate that primary neuroblastoma and
neuroblastoma cell lines express high levels of proteins
involved in HH signaling [17-19]. Additionally, inhib-
ition of this pathway at the level of GLI1 is more potent
than SMO blockade in reducing the cellular proliferation
of non-MYCN amplified neuroblastoma cell lines [19].
This suggests that GLI1 inhibition of HH signaling is an
effective way to target high-risk neuroblastoma without
MYCN amplification and should be considered as an op-
tion for neuroblastoma treatment.
The mammalian target of rapamycin (mTOR) has
emerged as a critical effector in cell signaling pathways
commonly deregulated in human cancers. mTOR regu-
lates cell growth by controlling mRNA translation,
ribosome biogenesis, autophagy, and metabolism [20].
Specifically, mTOR regulates translation by the phos-
phorylation of the ribosomal p70S6 kinase 1 (S6K1), which
promotes cap-dependent translation through phosphoryl-
ation of eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1) [21]. Full and sustained S6K1 activation
requires phosphorylation at amino acid residues T229,
located within the catalytic activation loop, and T389,
located at the hydrophobic motif [22]. Furthermore, the
phosphorylated and activated form of S6K1 (T389) is
decreased after treatment with the mTOR inhibitors
rapamycin or CCI-779 in neuroblastoma cells [23].
Additionally, the PI3K/mTOR inhibitor PI103 induced
time- and concentration-dependent inhibition of cell growth
in both MYCN and non-MYCN amplified neuroblastoma
cell lines [24].
Recently, the mTOR/S6K1 pathway was shown to medi-
ate the development of esophageal adenocarcinoma (EAC)
through GLI1 signaling [25]. Activation of the mTOR/
S6K1 pathway via S6K1 phosphorylation was demon-
strated to phosphorylate GLI1, promoting GLI1 transcrip-
tional activity and oncogenic function.
In this context, we explored if a crosstalk between
mTOR/S6K1 and HH signaling is relevant in neuroblast-
oma. Our data provide little support for a role of GLI1 sig-
naling as a mediator of the S6K1 proliferative effects in
neuroblastoma cells. S6K1 knockdown has minimal effects
on GLI1 signaling, GLI1 overexpression can not rescue the
reduced proliferation elicited by S6K1 knockdown, and
combinations of mTOR/S6K1 and GLI inhibitors do not
reveal additive or synergistic effects. Thus, we conclude
that S6K1 and GLI1 signaling exert proliferative effects on
neuroblastoma cells through independent mechanisms.
Methods
siRNAs and plasmids
siRNAs against S6K1 (RPS6KB1) (NCBI Reference Se-
quence: NM_003161.3) were designed and ordered fromDharmacon (SiGenome SMART pools, Thermo Scientific).
GLI1 siRNAs and control siRNAs were purchased from
Sigma-Aldrich.
S6K1 overexpression plasmids, wild type plasmid
S6K1WT, constitutively activated plasmid S6K1T389E
and function-loss plasmid S6K1T389A were kind gifts
of Mien-Chie Hung (University of Texas, MD Anderson
Cancer Center, Houston, TX). The GLI1 expression con-
struct (Flag-tagged) has been described previously [15].
Cell culture
Neuroblastoma cell lines SK-N-AS (non-MYCN-amplified,
high GLI1 expression) and SK-N-BE(2) (MYCN-amplified,
low GLI1-expression) [19,23,24], obtained from ATCC
(Manassas, VA), were cultured in RPMI-1640 with 10%
fetal calf serum and 100 IU/ml penicillin/streptomycin
and maintained in a 5% CO2 humidified incubator. RPMI-
1640, penicillin/streptomycin, and trypsin were purchased
from Invitrogen. Recombinant tumor necrosis factor alpha
(hTNF-α) was obtained from Roche Applied Sciences.
Transfection of siRNAs and expression constructs
Cells were plated in 6-well plates (5 × 105 cells per well)
or 10 cm2 dishes (3 × 106 cells per dish), and transfec-
tions were performed with Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s protocol (5 μl
Lipofectamine reagent per well for 6-well plate, and
10 μl for 10 cm2 dish). After each treatment, cells were
incubated at 37°C for 6 hours followed by a change to
fresh culture medium. Transfection efficiencies were
confirmed by siGLO (Green Transfection Indicator,
Dharmacon). To evaluate the effect of TNF-α, cells, after
a 48-hour transfection and overnight starvation, were
treated with TNF-α (5 ng/ml) for 6 hours. Cells were
harvested 48 or 72 hours after transfection for cell pro-
liferation assay, mRNA and protein analysis.
Cell proliferation
5 × 105 cells per well were seeded in 6-well plates, treated
with siRNAs for 48 hours, followed by a 4 hour 10 μM EdU
(5-ethynyl-2′deoxyuridine) incubation. EdU were detected
by fluorescent-azide coupling reaction (Click-iT, Invi-
trogen). For each treatment, 10 000 cells were analyzed
on a FACS calibur machine (BD Biosciences, Stockholm,
Sweden). Cell cycle distribution was calculated using the
CellQuest software (BD Bioscience). All proliferation ex-
periments were done at least in triplicate and representa-
tive experiments are shown.
Cell survival analysis
For cytotoxic evaluation, we used the fluorometric mi-
croculture cytotoxicity assay (FMCA), described in detail
previously [26]. Cells were seeded into drug-prepared
96- or 384-well microplates (SK-N-AS: 0.055×106 cells/ml,






















Figure 1 S6K1 and GLI1 knockdown reduces SK-N-AS cellular prolifer
control (siCN), GLI1 (siGLI1) or S6K1 (siS6K1) siRNAs, were subjected to the
with Alexa Fluor 488 azide was detected by flow cytometry. The data were
comparison using the GraphPad Prism software. Each bar represents the m
P < 0.05 compared to control. One representative experiment is shown in t
effective than the GLI1 siRNAs in reducing cellular proliferation.
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72 hours. The cells were washed, fluorescein diacetate
was added and after 40 minutes incubation, fluorescence
was measured. Cell survival is presented as survival
index (SI, %). The studies were designed as suggested in
the CalcuSyn software manual, using a fixed molar ratio
between the drugs (GANT61:AR-12 20:1; GANT61:
CCI-779 2:1 and GANT61:NVP-BEZ235 100:1), intended
to be equipotent. The IC50 values (inhibitory concentra-
tion 50%) were determined from log concentration-effect
curves in GraphPad Prism (GraphPad Software) using
non-linear regression analysis. Comparison between two
groups was made with t-test.
RNA preparation, cDNA synthesis and real-time PCR
Total RNA was isolated with the RNeasy mini kit (Qiagen,
Hamburg, Germany) according to the manufacturer’s
protocol. cDNA synthesis was performed with random
N6 primers (New England Biolabs) and Superscript III
(Invitrogen). Real-time PCR was carried out with Power
SYBR Green (Applied Biosystems, Foster City, CA) on a
7500 fast real-time PCR system (Applied Biosystems) with
primers designed to detect S6K1, GLI1, GLI2, GLI3, SMO
and PTCH2 (Table 1). All amplifications were run at leastation. SK-N-AS cells, cultured for 48 hours following transfection with
EdU incorporation assay for 4 hours. The percentage of cells labeled
analyzed with the one-way ANOVA test followed by Tukey’s multiple
ean ± SEM of three independent experiments. *, Statistical significant,
he histograph. Note that treatment with the S6K1 siRNAs is more
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pression of TATA binding protein (TBP). The relative ex-
pression was determined by the ΔCt method. All RNA
expression experiments were done at least in triplicate
and representative experiments are shown.
Western blot
For Western blotting, cells were lysed with RIPA buffer
(150 mM NaCl, 50 mM Tris base pH 8.0, 1 mM EDTA,
0.5% sodium deoxycholate, 1% NP-40, 0.1% sodium dode-
cyl sulfate, 1 mM DTT, 1 mM PMSF, and 1 mM Na3VO4)
supplemented with Complete Protease Inhibitor TabletsFigure 2 GLI1 but not S6K1 knockdown reduces GLI1, GLI2, GLI3, SMO
(C), GLI3 (D), the signaling molecule SMO (E) and the typical GLI1 target g
and S6K1, was determined by real-time PCR. Data are represented as relativ
the housekeeping gene TBP from the Ct value of the interrogated transcrip
indicate the standard deviation. *, Statistical significant, P < 0.02 compared(Roche) and phosphatase inhibitor (Sigma). Proteins were
separated on a 7.5% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (PAGE) followed by transfer (220 mA
for 1 hour) to an Immobilon-P membrane (Millipore). The
membrane was incubated at 4°C overnight in 5% skim milk
in TBST (Tris Buffered Saline with Tween 20) with anti-
rabbit GLI1 Ab (#2553, Cell Signaling) or anti-rabbit S6K1
Ab (sc-230, Santa Cruz Biotechnology) followed by incuba-
tion with goat anti-rabbit secondary antibodies for 1 hour
in 5% skim milk in TBST and visualized using chemilu-
minescent substrate (Thermo Scientific). The Western
blot experiments were done at least in triplicate and rep-
resentative experiments are shown.and PTCH2 expression. The expression of S6K1 (A), GLI1 (B), GLI2
ene PTCH2 (F) in SK-N-AS cells, following siRNA knockdown of GLI1
e expression (2-ΔΔCt values), calculated by subtracting the Ct value of
ts (ΔCt), and normalized to the ΔCt value obtained with siCN. Error bars
to control, calculated by the Student’s t-test.










Figure 3 GLI1 protein levels are unchanged following S6K1
knockdown. Western blot analysis of GLI1 and S6K1 protein
expression in SK-N-AS cells, following siRNA-mediated knockdown of
GLI1 and S6K1. Note the reduction of the GLI1 and S6K1 protein
bands by the siRNAs targeting GLI1 (siGLI1) and S6K1 (siS6), respectively.
siCN indicates the control siRNA treatment and β-Actin was used as the
endogenous protein control. Quantitation of protein expression, using
the ImageJ software, is shown in the bar graphs. Each bar represents
the mean ± SEM of triplicate values from a representative experiment. *,
Statistical significant, P < 0.01 compared to control, calculated by the
Student’s t-test using the GraphPad Prism software.
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For immunoprecipitation, cell lysates were generated
with lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl,
1 mM EDTA, 5% glycerol, 1% NP-40 and Protease/phos-
phatase inhibitor cocktail), and proteins immunoprecipi-
tated using anti-rabbit GLI1 Ab or healthy rabbit serum
and Protein A-Agarose according to the manufacturer’s
protocol (Santa Cruz Biotechnology). The protein/anti-
body/Protein A-Agarose complex was washed with PBS
containing 0.05% Tween 20. Cell lysates and immuno-
precipitated proteins on the transferred membrane were
incubated with anti-mouse GLI1 Ab (#2643, Cell Signal-
ing) for GLI1 or anti-mouse phosphoserine/threonine
Ab (612548, BD Transduction Laboratories) for phos-
phorylated GLI1, followed by incubation with goat anti-
mouse Ab. The immunoprecipitation experiments were
done at least in triplicate and representative experiments
are shown.
Results
S6K1 knockdown reduces cell proliferation
To investigate the role of S6K1 and GLI1 in neuroblast-
oma cellular proliferation, we first transfected SK-N-AS
cells with siRNAs targeting S6K1 or GLI1. This cell line
was chosen to initiate the analysis because of our previous
finding that its growth is most sensitive to GLI1 inhibition
[19]. 48 hours after transfection cell proliferation was ana-
lyzed using FACS. Introduction of S6K1 siRNAs into SK-
N-AS cells reduced cellular proliferation compared to the
corresponding siRNA control (Figure 1). Moreover, GLI1
siRNAs treatment also decreased proliferation but not to
the same extent as the S6K1 knockdown. Considering that
the knockdown of GLI1 and S6K1 kinase, determined by
real-time PCR analysis (Figure 2A and B) and Western
blotting (Figure 3) is comparable, we conclude that S6K1
silencing has stronger effects on SK-N-AS cellular prolif-
eration than GLI1 silencing.
GLI1, GLI2, GLI3, SMO and PTCH2 expression is insensitive
to S6K1 knockdown
To explore the biological mechanisms of S6K1 on SK-N-
AS cell proliferation and address the possible involvement
of HH signaling, we measured the RNA expression of sev-
eral key components of this pathway (GLI1, GLI2, GLI3,
SMO and PTCH2) following siRNA-mediated knockdown
of S6K1. Although the results clearly showed that the
S6K1 and GLI1 siRNAs reduced the expression of S6K1
and GLI1, respectively, the effects on the HH signaling
components were distinctly different. GLI1 knockdown
decreased the expression of the signaling molecule SMO,
the effectors GLI2 and GLI3, and PTCH2, which is known
to act as a target gene of the pathway [27], while this was
not the case with S6K1 knockdown (Figure 2). Similarly,
PTCH1, another target gene, is reduced by GLI1 but notS6K1 knockdown (data not shown). Importantly, GLI1 ex-
pression was unaffected by knocking down S6K1. Thus,
the mechanism of S6K1 on SK-N-AS cell proliferation is,
apparently, not related to the expression the HH signaling
components analyzed.
Moreover, the use of the SK-N-BE(2) neuroblastoma
cell line (Methods), which has low GLI1 expression com-
pared to SK-N-AS cells, also demonstrated that S6K1
knockdown has no effect on GLI1 mRNA levels. Finally,
treatment of either SK-N-AS or SK-N-BE(2) cells with
TNF-α, a cytokine that can induce S6K1 activity, failed
to show any S6K1 dependence on GLI1 expression
(Additional file 1: Figure S1).
BA
Figure 4 (See legend on next page.)
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Figure 4 SK-N-AS cellular proliferation is insensitive to S6K1 or GLI1 overexpression. (A) SK-N-AS cells, cultured for 48 hours following
transfection with control pCMV5 vector, and expression constructs for wild type S6K1 (S6K1 WT) constitutively activated S6K1 (S6K1T389E),
function-loss S6K1 (S6K1T389A) and GLI1, were subjected to the EdU incorporation assay for 4 hours. (B) SK-N-AS cells, cultured for 48 hours
following transfection with control siRNAs and pCMV5 vector (siCN + pCMV), S6K1 siRNAs and pCMV5 vector (siS6K1 + pCMV) and S6K1 siRNAs
and GLI1 expression construct (siS6K1 + pGLI1), were subjected to the EdU incorporation assay for 4 hours. The data were analyzed with the
one-way ANOVA test followed by Tukey’s multiple comparison using the GraphPad Prism software. Each bar represents the mean ± SEM of three
independent experiments *, Statistical significant, P < 0.01 compared to control. One representative experiment is shown in the histographs. For
both (A) and (B) the percentage of cells labeled with Alexa Fluor 488 azide was detected by flow cytometry. Note that overexpression of GLI1
can not rescue the reduced proliferation elicited by knocking down S6K1.
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has no detectable impact on GLI1 phosphorylation
In esophageal adenocarcinoma, S6K1 was demonstrated
to have the capacity to phosphorylate GLI1 increasing its
transcriptional activity [25]. We, therefore, tested whether
GLI1 may be subjected to S6K1-dependent phosphoryl-
ation in SK-N-AS cells. Initially, the protein levels of GLI1
were determined by Western blotting, revealing compar-
able expression prior and following S6K1 knockdown
(Figure 3). Subsequently, immunoprecipitation analysis
confirmed that the protein expression of GLI1 is not al-
tered by knocking down S6K1. Moreover, no GLI1 phos-
phorylation was observed, irrespective of the status of the
S6K1 (Additional file 1: Figure S2). Thus, in SK-N-AS
cells, S6K1-dependent phosphorylation of GLI1 is not tak-
ing place at detectable levels.
GLI1 overexpression can not rescue the reduced cell
proliferation elicited by S6K1 knockdown
Since knockdown of S6K1 causes a reduction in SK-N-
AS cellular proliferation, we asked whether overexpres-
sion of S6K1 might affect the proliferation of these cells.
However, ectopic expression of S6K1, the constitutively
activated mutant S6K1T389E or the function-loss mutant
S6K1T389A in SK-N-AS cells could not confer changes
in cellular proliferation (Figure 4A), even though pro-
tein expression was readily detected by Western blotting
(Additional file 1: Figure S3). This is in contrast to the
observations in EAC, where overexpression of S6K1 in-
creased cell proliferation [25]. Similarly, GLI1 overexpres-
sion did not augment proliferation (Figure 4A), again in
contrast to the EAC cells [25]. Consequently, our data
suggest that the proliferative effects of endogenous S6K1
and GLI1 have reached saturation in the SK-N-AS cell
line. Importantly, GLI1 overexpression could not rescue
the reduction of cell proliferation elicited by knocking
down S6K1 (Figure 4B). Thus, we conclude that the im-
pact of S6K1 on the proliferation of the neuroblastoma
SK-N-AS cells is not mediated through GLI1 signaling.
Combining GLI and PI3K/mTOR inhibitors does not
augment the growth reduction of neuroblastoma cells
To further examine the lack of observable interactions
between GLI1 and S6K1 signaling, the cytotoxicity of theGLI inhibitor GANT61 [28] and the PI3K/mTOR inhib-
itors, AR-12 (OSU03012), CCI-779 and NVP-BEZ235
was evaluated using FMCA not only in SK-N-AS but
also in SK-N-BE(2) cells, previously shown to be the least
dependent on GLI1 signaling [19] (Figure 5). No differ-
ences between the log IC50 of GANT61 and the log IC50
produced by the combination (t-test, p > 0.05), except for
the combination of GANT61 and CCI-779 in SK-N-BE(2)
cells (t-test, p = 0.032), was observed (Additional file 1:
Table S1).
Discussion
Deregulation of the HH signaling pathway has long been
known to be associated with various human cancers. Re-
cently, neuroblastoma was added to this list based on a
series of observations. GLI2, GLI3 and especially GLI1
knockdown reduced neuroblastoma cell growth compared
with siRNA control [19]. Moreover, GANT61, a GLI in-
hibitor, reduced the in vivo growth of high-risk neuroblast-
oma lacking MYCN amplification [19]. These findings
extend earlier reports, which indicated that inhibition of
HH signaling by cyclopamine induced apoptosis, blocked
proliferation and abrogated the tumorigenicity of neuro-
blastoma cells [18].
The HH signaling pathway is known to interact with
other signal transduction cascades during cancer devel-
opment, exemplified by the TGFβ – HH crosstalk in
pancreatic adenocarcinoma [10]. Recently, a connection
between the mTOR/S6K1 and the HH pathway has been
reported in EAC, through an S6K1-mediated GLI1 phos-
phorylation at Ser84, which increases its transcriptional/
oncogenic activity [25]. It should be noted that the S6K1
impact on GLI1 was observed following TNF-α treat-
ment, which activates S6K1. Without administration of
this cytokine there is little detection of active (phosphor-
ylated) S6K1 and phosphorylated GLI1. Furthermore,
knocking down S6K1 in HeLa cells had little effect on
GLI activity, unless AKT or ERK signaling was activated
[25]. In this study, we found that S6K1 knockdown is
more effective than GLI1 knockdown in reducing the
cellular proliferation of the non-MYCN amplified SK-N-
AS cell line. Additionally, knocking down S6K1 did not
affect GLI1 expression, irrespective of the treatment of
the cells with TNF-α. When the MYCN amplified and

























































































































Figure 5 Combination of small molecule inhibitors of GLI and PI3K/mTOR do not cooperate in inducing the suppression of
neuroblastoma cell growth. Dose–response curves for GANT61 cytotoxicity, in combination with the PI3K/mTOR inhibitors AR-12, CCI-779 and
NVP-BEZ 235, in SK-N-AS and SK-N-BE(2) cells treated for 72 h. The PI3K/mTOR inhibitors were tested in the following concentration spans: AR-12:
2 μM - 0.0078 μM, CCI-779: 20 μM – 0.078 μM and NVP-BEZ235: 0.4 μM - 0.0016 μM. A fixed ratio of GANT61 to the PI3K/mTOR inhibitors was
used in the combination experiments (GANT61:AR-12 20:1; GANT61:CCI-779 2:1 and GANT61:NVP-BEZ235 100:1). Note that no additive or synergistic
effects are seen in the combinatorial treatments except for the GANT61/CCI-779 combination in SK-N-BE(2) cells. This may relate to high concentration
of CC1-779 used compared to the other PI3K/mTOR inhibitors, which could elicit non-specific effects in this cellular context.
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was used, S6K1 knockdown did not change GLI1 expres-
sion in the absence of TNF-α. TNF-α treatment increased
GLI1 mRNA levels but this upregulation was insensitive
to S6K1 knockdown, arguing for the lack of involvement
of this kinase. Moreover, we could not detect changes in
the phosphorylation status of GLI1 by S6K1 knockdownin SK-N-AS cells. The most likely reason for this is that
the endogenous level of phosphorylated GLI1, if any, is
beyond the detection limit of the assay used. Another
possibility could be that the endogenous level of active
S6K1 may be too low to phosphorylate GLI1. However,
this is not supported by the fact that overexpression of
S6K1 does not elicit proliferation changes, while S6K1
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levels are sufficient for biological effects. In fact, active
(phosphorylated) S6K1 is readily detectable in the SK-
N-AS cell line [23]. Thus, our data suggest that GLI1 is
not a target of S6K1 and the impact of S6K1 on cellular
proliferation is independent of GLI1. This is further
supported by the inability of GLI1 overexpression to
rescue the reduced proliferation elicited by S6K1 knock-
down. Additionally, the combination of small molecule
inhibitors of GLI and PI3K/mTOR signaling revealed no
additive or synergistic effects on the suppression of neuro-
blastoma cell growth.
It should be also noted that a recent kinome-wide
siRNA screen in a non-small cell lung cancer cell line
revealed that S6K1 silencing does not alter the expres-
sion of GLI1 protein and GLI1 regulated genes [29], in
line with our observations in neuroblastoma. Further
analysis examining possible interactions between S6K1
and GLI1 in other cell types will provide additional clar-
ity on these issues.
Conclusion
Our experimental data demonstrate that in the context of
the neuroblastoma cells analyzed S6K1 kinase is not acti-
vating Hedgehog signaling through GLI1 phosphorylation.
These findings suggest that the effects of S6K1 and GLI1
signaling on neuroblastoma cell proliferation are mediated
through independent mechanisms.
Additional file
Additional file 1: Figure S1. GLI1 expression is not S6K1 dependent in
control or TNF-α treated SK-N-AS and SK-N-BE(2) cells. The expression of
S6K1 (A) and GLI1 (B) in SK-N-AS and SK-N-BE(2) cells transiently transfected
with siCN or siS6K1 followed by treatment with or without TNF-α (5 ng/ml)
was determined by real-time PCR as in Figure 2. Error bars indicate the
standard deviation. *, Statistical significant, P < 0.05 compared to control,
calculated by the Student’s t-test. Note, that in SK-N-AS cells TNF-α treatment
does not effectively modulate GLI1 expression. In SK-N-BE(2) cells it does, but
this GLI1 upregulation is not dependent on S6K1. Figure S2. S6K1 knockdown
does not change the levels of immunoprecipitated GLI1. SK-N-AS cells were
cultured for 48 hours following transfection with control (CN) or S6K1 (S6)
siRNAs and cell lysates were subjected to immunoprecipitation with rabbit GLI1
antibodies. Western analysis of lysates and immunoprecipitates was performed
with mouse GLI1 antibodies (upper panels) and mouse phosphoserine/
threonine antibodies (lower panels). Note the comparable GLI1 levels before
and after S6K1 knockdown and the absence of a signal for phosphorylated
GLI1. Figure S3. Expression constructs of S6K1 produce proteins in SK-N-AS
cells. SK-N-AS cells were cultured for 48 hours, following transfection
with control pCMV5 vector (pCMV), and expression constructs for wild
type S6K1 (S6K1 WT), constitutively activated S6K1 (S6K1T389E) and
function-loss S6K1 (S6K1T389A). Western blot analysis of cell lysates was done
with a rabbit S6K1 antibody. Note the co-migration of the endogenous and
exogenous S6K1 protein bands. Quantitation of protein expression, using the
ImageJ software, is shown in the bar graph. Table S1. Log IC50 values for
GANT61 and combination of GANT61 and PI3K/mTOR inhibitors on
neuroblastoma cell lines.
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